PTGX241220C5000
- 0.00
- 0.000.00%
Protagonist Therapeutics Newsroom
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Insider Sale: Chief Medical Officer of $PTGX (PTGX) Sells 16,000 Shares
Protagonist Therapeutics(PTGX.US) Officer Sells US$5.64 Million in Common Stock
Protagonist Therapeutics(PTGX.US) Officer Sells US$4.68 Million in Common Stock
Express News | Form 144 | Protagonist Therapeutics(PTGX.US) Officer Proposes to Sell 4.81 Million in Common Stocks
Express News | Form 144 | Protagonist Therapeutics(PTGX.US) Insider Proposes to Sell 4.59 Million in Common Stocks
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Protagonist Therapeutics (PTGX) Receives a Buy From Truist Financial
BTIG Downgrades Protagonist Therapeutics(PTGX.US) to Hold Rating, Raises Target Price to $67
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics Price Target Raised to $67 From $51 at BTIG
Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Express News | Protagonist Therapeutics Inc : Btig Raises Target Price to $67 From $51
Express News | Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)